NEW YORK (TheStreet) -- CHANGE IN RATINGS:Advance Auto Parts ( AAP - Get Report) upgraded at JP Morgan to overweight, JP Morgan said. Company can gain market share in an industry that's likely to see a soft landing in 2013. Aecom ( ACM) upgraded at BofA/Merrill from underperform to buy, Bank of America/Merrill Lynch said. $35 price target. Company is seeing a solid recovery in free cash flow. Activision Blizzard ( ATVI - Get Report) upgraded at Sterne Agee from neutral to buy, Sterne Agee said. $17 price target. Company is positioned well for the next business cycle and the company will likely buy back a significant amount of shares. Biogen Idec ( BIIB - Get Report) upgraded at Citigroup to buy from neutral, Citigroup said. $187 price target. Expecting a solid Tecfidera launch. Celgene ( CELG - Get Report) rated new outperform at JMP. $130 price target. Company is a market leader and can continue to deliver solid growth. Discover ( DFS) upgraded at Credit Suisse from neutral to outperform, Credit Suisse said. $47 price target. Company can deliver the best growth in the industry at the lowest valuation. DSW ( DSW) rated new buy at Sterne Agee. $75 price target. Company is a market leader and can deliver above-average growth for the foreseeable future. Guess ( GES) upgraded at Wedbush from neutral to outperform, Wedbush said. $34 price target. There are early signs that the business is turning around in North America. Gartner ( IT) downgraded at Piper from overweight to neutral, Piper Jaffray said. Valuation call, based on a $52 price target. Annaly Capital ( NLY) upgraded at Sterne Agee from underperform to neutral, Sterne Agee said. Valuation call, based on a $14.25 price target. Nuance ( NUAN) downgraded at Needham from buy to hold, Needham said. Company is seeing lower international sales and demand from healthcare customers. MetroPCS ( PCS) upgraded at Nomura from reduce to neutral, Nomura said. $9.50 price target. Worst news appears to be behind the company. Riverbed ( RVBD) downgraded at FBR from outperform to market perform, FBR Capital Markets said. $20 price target. Company is seeing lower core sales.
STOCK COMMENTS / EPS CHANGESBiogen Idec ( BIIB - Get Report) numbers increased at Credit Suisse. BIIB estimates were raised through 2016, Credit Suisse said. Tysabri deal should add to earnings. Outperform rating and new $185 price target. Cigna ( CI) numbers raised at Jefferies. Shares of CI now seen reaching $71, Jefferies said. Estimates also raised on its upward 2013 revision. Buy rating. Cisco ( CSCO - Get Report) target raised at Citigroup to $24, Citigroup said. Continued execution in an improving macro environment. Buy rating. Coinstar ( CSTR) estimates, target cut at JP Morgan.CSTR estimates were reduced through 2014, JP Morgan said. Company is seeing lower sales. Neutral rating and new $51 price target. Eastman Chemical ( EMN) target raised at Jefferies. Shares of EMN now seen reaching $79, Jefferies said. Favorable pricing in 2013. Hold rating. Google ( GOOG - Get Report) added to Best Ideas List at Morgan Stanley. Company can deliver 15% compound annual free cash flow growth over the next five years. $932 price target. CarMax ( KMX) numbers raised at Oppenheimer. Shares of KMX now seen reaching $46, Oppenheimer said. Estimates also raised on attractive market share growth. Outperform rating. LinkedIn ( LNKD) estimates, target raised at BMO. Shares of LNKD now seen reaching $130, according to BMO Capital. Estimates also increased, as new products are driving growth. Market Perform rating. Microchip Technology ( MCHP) numbers raised at Jefferies. Shares of MCHP now seen reaching $41, Jefferies said. Estimates also raised on fourth quarter beat. Buy rating. Microchip estimates, target raised at Credit Suisse. Shares of MCHP now seen reaching $40, according to Credit Suisse. Estimates also increased, as the company is seeing higher core demand and benefits from acquisitions. Outperform rating. Martin Marietta ( MLM) numbers raised at Jefferies. Shares of MLM now seen reaching $114, Jefferies said. Estimates also raised stronger demand enabling fourth quarter beat. Buy rating. NCR ( NCR) estimates, target boosted at JP Morgan. Shares of NCR now seen reaching $37, according to JP Morgan. Estimates also upped, given the company's new guidance. Overweight rating. OpenTable ( OPEN) numbers lowered at Oppenheimer. Shares of OPEN now seen reaching $49, Oppenheimer said. Estimates also lowered on slowing earnings growth. Perform rating. Patterson-UTI ( PTEN) numbers upped at BMO. PTEN estimates were boosted through 2014, BMO Capital said. Company is seeing higher demand for pressure pumping. Outperform rating and new $25 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.